Connect Biopharma (NASDAQ:CNTB) Chief Executive Officer Barry Quart said the company’s rademikibart program continues to show a differentiated clinical and mechanistic profile as the company awaits mid-2026 data from its SEABREEZE study.
Speaking during a fireside chat with H.C. Wainwright analyst Brandon Folkes, Quart said rademikibart, an IL-4 receptor alpha monoclonal antibody, has demonstrated clinical characteristics that differ from what is typically expected from the class. He compared the mechanism category to Dupixent but said rademikibart has shown a different profile, including lowering eosinophils in asthma patients.
